Sputnik Light demonstrates a good safety profile and efficacy against COVD-19

Considerations are being made whether the vaccine can be a standalone vaccine or used for re-vaccination.



Clinical trial results published from The Lancet medical journal have indicated that Sputnik Light has a good safety profile. The results also show that the vaccine elicits a strong immune response in people who have already been infected by the COVID-19 virus. Sputnik Light is a single dose version of Sputnik V, which is a two-dose vaccine that was presented last year. Sputnik V is currently being broadly used in Russia and has been approved for use in 71 countries, however Russia plans to make the single dose vaccine its main vaccine export. The researchers stated that, "Sputnik Light might be considered not only for primary vaccination, but also could be useful as an efficient tool for further revaccination or vaccination after previous COVID-19 infection."


Sputnik Light’s virus neutralization against the Alpha and Beta strains showed a statistically significant decrease in antibody response. The vaccine has showed positive results when it comes to the Delta variant, which is the dominant strain currently in Russia. The vaccine was 70% effective against the Delta variant three months post vaccination. Mikhail Murashko, the Minister of Health in Russia stated that the ministry recommends that Sputnik Light be used only for re-vaccination. The executive branch of the government of Russia, also known as the Kremlin, however remarked that Sputnik Light can be administered as a standalone vaccine. "We believe Sputnik Light vaccine could contribute towards accelerating the pace of vaccination in Russia as well as in other countries that are lacking sufficient vaccine supply," the researchers wrote.